In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Biotechnology
Germany’s Evotec says it has taken notice of the statement made by Halozyme Therapeutics on November 22, stating that it has withdrawn its non-binding proposal to acquire Evotec for 11.00 euros per share in cash. 23 November 2024
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Biotechnology
Sweden-based BioArctic saw its fall 7.5% to 139.90 kronor on Friday, after its announced that its partner, Japan’s Eisa, has updated its revenue outlook for the Alzheimer’s treatment Leqembi (lecanemab) for the 2024 fiscal year (FY), which runs from April 2024 through March 2025. 11 November 2024
Biotechnology
Danish biotech Gubra announces that Germany’s Boehringer Ingelheim has decided to discontinue the development of the long-acting neuropeptide Y receptor type 2 (NPY2R) agonist BI 1820237 in obesity. 4 November 2024
Biotechnology
Japanese drugmaker Eisai has completed the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (US brand name Leqembi) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. 1 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Biotechnology
Sirnaomics, a firm specializing in RNAi therapeutics, has entered into a subscription agreement with biotech specialist Poon Hung Fai. 4 October 2024
Biotechnology
GigaGen has been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the US Department of Health and Human Services (HHS). 4 October 2024
Biotechnology
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
article
The European Medicines Agency’s (EMA) Committee for Human Medicinal Products (CHMP) has elected Bruno Sepodes as its new chair. 19 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Biotechnology
Zenas BioPharma announced the pricing of its upsized initial public offering of 13,235,294 shares of its common stock at an initial public offering price of $17.00 per share. 13 September 2024
Pharmaceutical
A feature analyzing how - and why - cardiology is of renewed interest to pharma. 17 November 2023
Biotechnology
Leading checkpoint blocker Keytruda (pembrolizumab) has picked up a new American approval, in combination with chemotherapy, for the first-line treatment of certain people with gastric cancer. 17 November 2023
Biotechnology
Astellas and Pfizer’s Xtandi (enzalutamide) has won a new approval in prostate cancer from the US Food and Drug Administration (FDA). 17 November 2023
Biotechnology
Almirall has won European Commission (EC) approval for Ebglyss (lebrikizumab) for the treatment of adult and adolescent patients with moderate-to-severe atopic dermatitis (AD), who are candidates for systemic therapy. 17 November 2023
Biotechnology
Utah, USA-based biotech Halia Therapeutics has appointed Lisa Shamon as vice president of regulatory affairs and Xianne Penny as a senior medical director. 17 November 2023
Biotechnology
The European Commission (EC) has granted marketing authorization for China-headquartered biotech BeiGene’s Brukinsa (zanubrutinib) in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma. 17 November 2023
Generics
The US unit of Israeli generics giant Teva Pharmaceutical Industries has received US Food and Drug Administration (FDA) approval of a generic version of Forteo (teriparatide). 17 November 2023
Biotechnology
The Food and Drug Administration yesterday granted approval for UK pharm major AstraZeneca’s (LSE: AZN) Truqap (capivasertib) with Faslodex (fulvestrant). 17 November 2023
Pharmaceutical
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending Jardiance (empagliflozin) as an option for the treatment of eligible adults with chronic kidney disease (CKD) in England and Wales. 17 November 2023
Pharmaceutical
A worrying drop in the number of clinical trials launched in the UK could be coming to an end, early figures suggest. 17 November 2023
Pharmaceutical
GLP-1 agonists are transforming the way cardiometabolic disorders are treated, with new approvals in obesity opening the door to significant new treatment opportunities. 17 November 2023
Biotechnology
Japanese drugmaker Daiichi Sankyo revealed it has reached an agreement with Japan’s Ministry of Health, Labor and Welfare (MHLW) to supply the omicron XBB.1.5- adapted monovalent mRNA vaccine (DS-5670) against the novel coronavirus infectious disease (COVID19). 17 November 2023
Pharmaceutical
The UK’s Competition and Markets Authority (CMA) has clarified the circumstances under which it will not prioritize enforcement action against pharmaceutical companies when they implement a specific ‘negotiation framework’ to make more combination therapies available on the National Health Service (NHS). 17 November 2023
Biotechnology
Boston, USA-based biotechnology start-up PostEra, which specializes in artificial intelligence for pre-clinical drug discovery, has entered into a multi-target collaboration with US biotech major Amgen. 17 November 2023
Biotechnology
US drug developer SpringWorks Therapeutics today announced what it described as positive top-line results from its Phase IIb ReNeu trial evaluating mirdametinib. 16 November 2023
Biotechnology
Bristol Myers Squibb has announced that the US Food and Drug Administration (FDA) has approved Augtyro (repotrectinib) to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). 16 November 2023
Biotechnology
French specialty vaccines developer Valneva’s last week received approval of Ixchiq from the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya virus (CHIKV) vaccine. 16 November 2023
Pharmaceutical
Vision-focused biopharma LENZ Therapeutics and Graphite Bio have entered into a definitive merger agreement to combine the companies in an all-stock transaction. 16 November 2023
Biotechnology
A new cell therapy company has launched in Cambridge, UK, with $59 million in series A funding provided by Sofinnova Partners and others, including Sanofi Ventures. 16 November 2023
Pharmaceutical
Japanese pharma major Astellas Pharma has entered into a merger agreement to acquire Propella Therapeutics. 16 November 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze